Food Effect and Relative Bioavailability Study of VC004 Capsules in Healthy Adult Subjects

NCT06529445 | Completed Phase 1

• 1 other identifier: VC004-105
• Study Type: interventional
• Target: 84
• Locations: 1 country
• Sites: 1

Brief Summary

This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect and Relative bioavailability of VC004 Capsules in healthy subjects

Conditions

Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

Outcome Measures

Primary Outcomes (3)

• Maximum Observed Plasma Concentration (Cmax)

  Day1-Day7

• Peak time(Tmax)

  Day1-Day7

• Area Under the Curve From Time Zero to Last Quantifiable Concentration(AUC）

  Day1-Day7

Study Arms (3)

High Dose VC004 group

EXPERIMENTAL

Drug: High Dose VC004 Capsules

Median Dose VC004 group

EXPERIMENTAL

Drug: Median Dose VC004 Capsules

Low Dose VC004 group

EXPERIMENTAL

Drug: Low Dose VC004 Capsules

Interventions

High Dose VC004 Capsules DRUG

VC004 Capsules qd per period, for two periods

High Dose VC004 group

Median Dose VC004 Capsules DRUG

VC004 Capsules qd per period, for two periods

Median Dose VC004 group

Low Dose VC004 Capsules DRUG

VC004 Capsules qd per period, for two periods

Low Dose VC004 group

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;
• Able to complete the study in compliance with the protocol;
• Subject (including partner) is willing to voluntarily take effective contraceptive measures from screening through 6 months after the last dose of study drug (see Appendix 5 for details);
• Male and female subjects between the ages of 18 and 45 years, inclusive;
• At least 50.0kg for male subjects, 45.0kg for female subjects, with a Body Mass Index (BMI= Weight/Height2) between 19.0-26.0 kg/m2, inclusive;

You may not qualify if:

• More than 5 cigarettes per day on average within 3 months prior to screening;
• with a history of allergies, including medication, food, mites, etc., or those known to be potentially allergic to drugs of the same class as the study drug;
• History of drug and/or alcohol abuse (alcoholism defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or or have used drugs within the past five years;
• Donation or loss of a significant volume of blood (\> 400 mL) within 3 months prior to screening;
• History of difficulties in swallowing or any history of gastrointestinal(such as reflux esophagitis, peptic ulcer, chronic diarrhea, chronic constipation), liver, kidney disease (whether cured or not) or surgery that affects drug absorption or excretion within 6 months prior to screening;
• Those who Have taken strong inhibitors and / or inducers of liver metabolic enzymes (CYP1A2, 2A6, 2b6, 2c8, 2c19, 3A4 and 3A5) within 28 days prior to screening :strong inhibitors of liver metabolic enzymes such as ciprofloxacin, clopidogrel, itraconazole, ketoconazole, ritonavir, oleandomycin etc., strong inducers of liver metabolic enzymes such as rifampicin, carbamazepine, phenytoin sodium, St. John's wort, etc; Those who Have taken inhibitors and inducers of P-gp, MRPs, BCRP, OATP and other transporters and transporters within 28 days prior to screening; See Appendix 5 for details;
• Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to screening;
• Taking foods that affect CYP3A4 metabolism, such as grapefruit or drinks containing grapefruit within 2 weeks prior to screening, or taking high-intensity physical exercises (such as strength training, aerobic training and football playing) within 7 days prior to screening, or any other factors that affect drug absorption, distribution, metabolism and excretion;
• Participated in other clinical trials within 3 months before screening (if the subject withdraws from the study before treatment, i.e. has not been randomized or received treatment, he or she can be enrolled in the study);
• Those who cannot tolerate high-fat meals or have special requirements for diet and cannot accept unified diet；
• A clinically significant vital signs abnormality during screening (body temperature (axillary temperature) \< 36.0 ℃ or \> 37.0 ℃; Pulse \< 60bpm or \> 100bpm; Systolic blood pressure \<90mmhg or ≥ 140mmHg, diastolic blood pressure \<60mmhg or ≥ 90mmHg);
• A clinically significant 12-lead ECG abnormality;
• Positive test results of blood pregnancy or is lactating for female subjects;
• Any clinically significant abnormalities/findings in laboratory tests, or any clinically significant disease including but not limited to gastrointestinal, renal, hepatic, neurological system, blood, endocrine, tumor, lung, immune, mental, or cardiovascular and cerebrovascular diseases;
• Positive test results for viral hepatitis (including hepatitis B and C), HIV antibody or syphilis antibody during screening;

Sponsors & Collaborators

• Jiangsu vcare pharmaceutical technology co., LTD: lead

Study Sites (1)

Zhongda Hospital,Affiliated to Southeast University

Nanjing, Jiangsu, 210009, China

Location

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 26, 2024
• First Posted: July 31, 2024
• Study Start: July 22, 2024
• Primary Completion: August 26, 2024
• Study Completion: August 26, 2024
• Last Updated: August 29, 2024

Record last verified: 2024-07

Locations

CN (1)